Prognosis of the risk progression of post-inflammatory pneumofibrosis in children with chronic nonspecific lung diseases

Introduction. Pneumofibrosis (PF) is a morphological outcome of acute and chronic lung diseases, the progression of which leads to organ deficiency.

Aim. Development of a prognostic algorithm for assessing the risk of progression of post-inflammatory PF in children with chronic nonspecific lung diseases (CNSLD).

Materials and methods. The examination of 52 children with CNSLD with focal post-inflammatory PF was conducted, of which 26 children with progressive PF and 26 children with non-progressive PF. The children were selected according to the “case-control” scheme. The patients had a dynamic clinical and laboratory examination with multispiral computed tomography of the lungs. Determination of the “zero” genotypes of the detoxification genes GSTM1, GSTT1 was carried out by means of polymerase chain reaction. The odds ratio indicator was used to assess the relative risk.

Results. Based on the analysis of medico-social, clinical characteristics and genetic polymorphism, an individual prognostic algorithm for the risk of progression of post-inflammatory PF in children with CNSLD was developed. The algorithm includes the calculation of the total score (TS) of 7 medical and social indicators (living in an urban area; the presence of passive smoking; the duration of a pulmonological history of 4-9 years; the presence of congenital lung malformation; the number of acute respiratory infections (ARI) 4 or more times/year; the duration of ARI 11 days or more; taking antibiotics for more than 3 once/year) and the presence of deletions in the detoxification genes GSTM1 and GSTT1. With a value of TS 6.97 or more, a high risk of progression of PF is predicted, with TS 3.47-6.96 points, a moderate risk of progression of PF is diagnosed, with TS 3.46 or less points, a minimal risk of progression of PF.

Conclusion. The proposed algorithm allows predicting the risk of progression of post-inflammatory PF in children with CNSLD at the stage of early diagnosis and will prevent the spread of the process in the lungs with the help of preventive measures and preventive therapy, which will increase the duration and improve the quality of life of the patient.

1. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009; 2(2):103–121. https://doi.org/10.1038/mi.2008.85

2. Kim H.R., Shin D.Y., Chung K.H. A review of current studies on cellular and molecular mechanisms underlying pulmonary fibrosis induced by chemicals. Environ. Health Toxicol. 2018; 33(3):e2018014. https://doi.org/10.5620/eht.e2018014

3. Pustovetova M.G., Chikinev Y.V., Piontkovskaya K.A., Drobyazgin E.A., Samsonova E.N. [Features of pathogenesis of fibrosis at bullous lung disease]. Meditsina i obrazovaniye v Sibiri = Journal of Siberian Medical Sciences 2014; (5):36 (in Russian).

4. Kotlyarov P.M., Egorova E.V., Rebrikova V.A. [Virtual Bronchoscopy in the Refined Diagnosis of Lung Pathology]. Difficult Patient 2018; 16(11):50–53 (in Russian). https://doi.org/10.24411/2074-1995-2018-10031

5. Speranskaya A.A., Novikova L.N., Baranova O.P., Dvorakovskaya I.V., Kameneva M.Yu., Amosova N.A. [Computed tomography in evaluating the development of different types of pulmonary fibrosis in patients with interstitial lung diseases]. Vestn. Rentgenol. Radiol. 2015; (4):5–11 (in Russian). PMID: 26552223.

6. Lechowicz K., Drozdzal S., Machaj F., Rosik, J., Szostak B., Zegan-Barańska M., Biernawska J., Dabrowski W., Rotter I., Kotfis K. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J. Clin. Med. 2020; 9(6):1917. https://doi.org/10.3390/jcm9061917

7. Vinokurov A.S., Zyuzya Yu.R., Yudin A.L. [Evolution of follow up CT signs in patients with COVID-19 in early stage]. Diagnostic Radiology and Radiotherapy 2020; 11(2):76–88 (in Russian). https://doi.org/10.22328/2079-5343-2020-11-2-76-88

8. Baranov V.S., editor. [The genetic passport – the basis of individual and predictive medicine]. St. Petersburg: N-L; 2009 (in Russian). ISBN: 978-5-94869-084-1.

9. Board P.G., Menon D. Glutathione transferases, regulators of cellular metabolism and physiology. Biochim. Biophys. Acta. 2013; 1830(5):3267–3288. https://doi.org/10.1016/j.bbagen.2012.11.019

10. Khorinko A.V., Amarantov D.G., Kosareva P.V. [The Role of the Disorders of Cell Matrix Interactions in the Pathogenesis of Pulmonary Fibrosis Progression]. Journal of Anatomy and Histopathology 2016; 5(3):84–89 (in Russian). https://doi.org/10.18499/2225-7357-2016-5-3-84-89

11. Blokhin B.M., editor. [Pediatric pulmonology: national guidelines]. Moscow: GEOTAR-Media; 2021 (in Russian). ISBN: 978-5-9704-5857-0

12. Jordan B.K., McEvoy C.T. Trajectories of Lung Function in Infants and Children: Setting a Course for Lifelong Lung Health. Pediatrics 2020; 146(4):e20200417. https://doi.org/10.1542/peds.2020-0417

13. Martinez F.D. Early-Life Origins of Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2016; 375:871– 878. https://doi.org/10.1056/NEJMra1603287

14. Ilkovich MM, Novikova LN, Speranskaya AA, Dvorakovskaya IV. [Progressive fibrosing lung disease. Discussion aspects of the problem: A review]. Ter. Arkh. 2023; 95(3):255–259 (in Russian). PMID: 37167148. https://doi.org/10.26442/00403660.2023.03.202075